
ETHICAL REVIEW COMMITTEE, ICODE, B.

The state of the s	willier, reduk's.
Principal Investigator Dr.M.H.Munshi	Trainee Investigator (if any)
Application No. 88-004	Supporting Agency (if Non-ICDDR, B)
itle of Study ICDDR, B SURVEILLANCE	** ***********************************
PROGRAMME, TEKNAF TREATMENT CENTRES.	Project status: () New Study
PROGRAMME, TERMAT INDITITED	() Continuation with change
A.	
	No change (do not fill out rest of form)
Source appropriate answer to each of	the following (If Not Applicable write NA).
(0) (1)	5. Will signed consent form be required:
(b) We would be the second of	(a) From subjects Yes (No)
(c) Minors or persons	(b) From parent or guardian
tindan market and a	(if subjects are minors) Yes (No)
noos the study involve:	6. Will precautions be taken to protect
(a) Physical risks to the	anonymity of subjects (Yes) No
subjects Yes (No)	 Check documents being submitted herewith to Committee:
(b) Social Risks Yes (No)	·
(c) Psychological risks	Umbrella proposal - Initially submit a
to subjects Yes (No)	overview (all other requirements will
(a) Discomfort to subjects Yes (No)	be submitted with individual studies). Protocol (Required)
nvasion of privacy (red No	Abstract Summary (Required)
(r) Disclosure of informa-	Statement given or read to subjects on
tion damaging to sub-	nature of study, risks, types of quest
ject or others / Yes (No)	ions to be asked, and right to refuse
Does the study involve: (a) Use of records (here	to participate or withdraw (Required)
· · · · · · · · · · · · · · · · ·	Informed consent form for subjects
ital, medical, death, birth or other) (Yes) No	Informed consent form for parent or
(b) Use of fetal tissue or	guardian
abouting table of	Procedure for maintaining confidential
(c) Use of organs or body	/ ity
fluids Yes (No)	Questionnaire or interview schedule +
Are subjects clearly informed about:	" If the final instrument is not completed
(a) Nature and purposes of	prior to review, the following information
andy (Yes) No	should be included in the abstract summar.
(b) Procedures to be	A description of the areas to be
followed including	covered in the questionnaire or interview which could be considered
alternatives used Yes No	either sensitive or which would
(c) Physical risks Yes (No)	constitute an invasion of privacy.
consitive questions Yes (No.	2. Examples of the type of specific
	questions to be asked in the sensitive
- But the variable fo	areas.
participate or to with- draw from study (Yes) No	3. An indication as to when the question-
(g) Confidential handling	naire will be presented to the Cttre.
	for review.
(h) compensation 6/or treat-	
ment where there are risks	•
or privacy is involved in	
ny particular procedure yes (No)	
agree to observe	(PTO)
agree to obtain approval of the Ethical volving the rights and welfare of subject	Review Committee for any changes
olving the rights and welfare of subject	s before making such change.
& namo (1)	•
Pincipal Investigator	
Y and Anna Partition	Trainee

NI 407 JB2 M 9691 1988



SECTION I RESEARCH PROTOCOL

ICDDR, B Surveillance Program, Teknaf Treatment Centres. Title 1.

Dr. M.H. Munshi 2.1. Principal Investigator

Dr. M.A. Islam 2.2. Co-Investigator

: Jan-01, 1988 3. Starting date

To be continued as long as the Completion date

Centre requires.

: a) US\$ 23,822 Source of funding - USAID/Coop (TS) Total direct cost 5. _ **b**)

Approval: 6.

> This protocol has been approved by the Laboratory Sciences Division.

Abstract Summary

Teknaf is an endemic area for shigellosis and other diarrhoeal diseases. Over 5,000 patients are being treated annually at the ICDDR,B Treatment Centres in Teknaf. The surveillance Ppogram aims to evaluate the various clinical, epidemiological and microbiological data collected from all the patients attending ICDDR, B Treatment centres in Teknaf. This will be used to determine the spectrum of diarrhoeal diseases in Teknaf which possesses distinct socio-demographic-climatic characteristics in respect to other parts of rural Bangladesh.

The surveillance program will be the routine activity of the ICDDR, B treatment centres in Teknaf. Regular and necessary treatments will be provided to all patients by the usual clinical staff in the treatment centre. A questionnaire will be used in the treatment centre to obtain necessary information and a fresh sample of stool / RS will be collected from each patient for investigations. The patients/attending gurdians will be interviewed and the patients will be examined by the usual clinical staff in the treatment centre. The Surveillance Program will help us to monitor the spectrum of diarrhoeal diseases in Teknaf and to generate new ideas for further research into the control of diarrhoeal diseases, particularly shigellosis.

8. Reviews:

a)	Ethical Review Committee:	
b)	Research Review Committee:	سبب المام يوف موف يوف موف المام ا المام يوف المام يوف المام
c)	Director:	

SECTION II RESEARCH PLAN

A. INTRODUCTION

1. Objective:

Teknaf, during the last 12 years, has been found to be endemic area for shigellosis with frequent epidemic outbreaks. During the last few years, Teknaf also experienced periodic Cholera epidemics. S.dysenteriae type 1 strains isolated in Teknaf have become resistant to commonly used antibiotics including Nalidixic acid. During 1987 over 5,000 patients attended in the ICDDR, B Treatment centres in Teknaf, attendance is increasing. The objective of this Surveillance Program is to evaluate detailed clinical, epidemiological and microbiological data from the patients attending ICDDR, B Treatment Centres in Teknaf. The surveillance data will analysed on an ongoing basis.

- 01. To permit early recognition of seasonal or localised diarrhoeal outbreaks in the Teknaf area.
- 02. To determine the aetiologic agents of diarrhoea in Teknaf.
- 03. To study the changing trend of Shigella isolations and their antibacterial sensitivity in the Teknaf area.
- 04. To identify the evidence of outbreak of MARVc in Teknaf.
- 05. To generate new ideas for further research appropriate for controlling diarrhoeal diseases, particularly shigellosis.

2. Background

diseases are the major public health problems in Diarrhoeal developing Diarrhoea is the leading cause of death world. young children and constitutes an important contributing malnutrition. Diarrhoea is recognised as one of important cause of morbidity and mortality in Bangladesh similar developing countries (LC Chen, et al, 1977; WJ Van Zijil, 1966; WR Baker, et al, 1975; JA Walsh, et al, 1979; RE et al. et al. 1980, LC Chen, et al, 1980). Shigellosis is a serious disease in childhood, particularly for children who are malnourished. The problem of increasing resistance to the drugs used to treat shigellosis means that shigellosis is a in Bangladesh and in the other parts of problem (ICDDR,B Annual Report, 1986,pp-25).

Teknaf is an endemic area for shigellosis with frequent epidemic outbreaks. The study of the transmission of shigellosis in Teknaf can considerably expand the understanding of the epidemiology of shigellosis.

The Teknaf Upazila is situated at the South-eastern tip of Bangladesh in the Cox's Bazar district. It is a narrow peninsula. The eastern side is bounded by the Naf river bordering Burma and the western side is circumscribed by the Bay of Bengal. The Upazila is about 55 KM long and about 6 KM wide. Almost two-thirds of the Upazila are hilly areas, constituting a part of the Reju-Teknaf range of reserved forest where human habitation is

not permitted. Human habitation is limited to the western bank of the Naf, the beach area on the western side and the southern plain.

A motorable road about 85KM long, links Teknaf and the district headquarter of Cox's Bazer. The communication within the Upazila is mainly on foot by the dirt roads. The water transport in the Naf river and motor transport along the beach is not properly developed, but used only during the winter season.

The climate of Teknaf is sub-tropical with three distinct seasons: monsoon, cool-dry and hot-dry. Monsoon usually starts in June and continues until September. Most of the 510 cms of average annual rainfall occurs during this season. It often rains several times daily with heavy showers, and it often rains continuously for days together. Due to the very quick natural drainage of rain water to the Bay of Bengal, the people of Teknaf are not inundated with flood-water as are the people of the deltaic and flooded regions of Bangladesh. Then follows the cooldry season, which is very pleasant and extends until February. The hot-dry season begins in March and ends with the beginning of monsoon.

As there is a rocky layer underground, shallow tube-wells (hand pumps) cannot be installed in most of the habitable regions of Teknaf. As a result, the people are dependent on the polluted surface water from the dug-wells for their drinking and domestic uses. The usual water sources are ditches and ring-wells. Most

of the shallow water sources run dry and water shortages occur during the hot-dry season.

Almost all the people in Teknaf are Bangladeshi Muslims with conservative outlooks. There are a negligible number of tribal people in Teknaf. About ten percent of the population is literate. The principal occupations of the people are cultivation and fishing.

Rice grows in Teknaf only in monsoon, but plenty of betel leaves and betel nuts grow there. Large quantities of seafishes are caught in the Naf river and the Bay of Bengal. Consumption of good amount of fish results in good nutritional status, and absence of vitamin A deficiency in the community, but nutritional deficiencies in children have been observed in the pre-harvest period.

Crowding is relatively common in Teknaf. A few years ago, almost all the houses had earthen floor, bamboo walls and roofs made of leaves and straws. But very recently, due to the huge amount of foreign remittances from the Arab countries and the yields of border-tradings, Teknaf area has experienced a very rapid socio-economic change, resulting in the construction of pucca dwelling houses. Unfortunately, the literacy rate remains the same. Though the development process has already been initiated in Teknaf, it will not be possible to develop public health facilities in the near future. Due to the various topographical, climatic and other socio-cultural reasons, including crowding and rapid transition of population across the international border,

Teknaf still remains a hyper-endemic area for diarrhoeal diseases. Almost every year, at the beginning of monsoon, epidemic outbreaks are sure to occur.

ICDDR,B (former CRL) activities in Teknaf area in the form of a diarrhoeal disease treatment and surveillance program were instituted in later part of 1974 after a severe out break of dysentery caused by multiresistant Shigella dysenteriae type 1 (MM Rahaman, et al, 1975). A census was taken in December, 1974 and January, 1975 of Teknaf Upazila. Demographic and diarrhoeal surveillance was initiated in 1976 with a population of about 46,000 in 4 Union Parishad areas.

The diarrhoea treatment centre provided free services to the community for diarrhoeal diseases, was staffed by a Physician, a Nurse and other staff. The treatment centre was backed up by a field laboratory with the facilities of stool microscopy and bacteriological cultures for common enteric diseases. The field laboratory was equipped with innovative technologies such as kerosene run refrigerator, kerosine-run incubator (egg hatcher), pressure cookers and demineralizer.

The beach area was covered by a chain of community-based ORS distribution centres. In 1980, the Water and Sanitation Intervention Study was undertaken in a Community and the study was completed in 1983. Regular diarrhoea surveillance was discontinued in 1981. A second demographic census was taken in 1982. A new village was included and a new demographic surveillance at monthly interval was initiated in 1983 under the

DSS-Teknaf protocol, in a population of about 61,000. Since the starting of ICDDR, B (former CRL) activities in Teknaf, a number of scientific publications have been made using the information generated through the surveillance and treatment centre programmes.

The demographic characteristic of Teknaf are quite remarkable, with a very high Crude Birth Rate and a high marital separation rate. The CBR in Teknaf is the highestin Bangladesh. The IMR in Teknaf has been recorded in 1983 as 153.8 (M. Rahman, et al, 1983 ICDDR, B Scientific Report # 66, pp-4). One out of five deaths in children of age 1-4 yrs in 1977 was caused by diarrhoeal illness (M. Rahman, et al, 1979 ICDDR, B Working Paper # 13, 1979, pp-24); and for the years 1982 - 1985, 23% deaths in children between 1 and 59 months of age were attributed to diarrhoea and dysentery (ICDDR, B Annual Report, 1986, pp-37).

Since the inception of ICDDR, B activities, Teknaf has been found to be endemic for shigellosis, the predominant strain is Sifiexmeriae. The proportion of patients attending treatment centre with loose/watery diarrhoea was found to be less than 20 % during the years 1976 to 1980, but the proportion has increased to 33 % in 1986. During 1986, 201 Vibrio Cholerae isolates were made in the field laboratory.

During 1986, there were simultaneous epidemics of cholera and shigellosis due to <u>S.dysenteriae</u> type 1. The strains of <u>S.dysenteriae</u> I isolated were resistant to most of the commonly used antibiotics. Nalidixic acid was introduced in the middle of

1986, but resistance to nalidixic acid was detected and the percentage of the resistant cases increased over time. By the end of 1986, nalidixic acid became virtually useless for the treatment of shigellosis caused by <u>S.dysenteriae</u> I in Teknaf. Previously, resistance to nalidixic acid was thought not to be associated with a transferable plasmid; however, in Teknaf, resistance to nalidixic acid appears to be mediated by a 20 megadalton plasmid (MH Munshi, et al, 1987). As we have begun using Pivmecillinum as the only currently available antibiotic in Bangladesh to treat patients infected with resistant <u>S.dysenteriae</u> type I strains, the monitoring for the resistance to this drug in the community is highly imperative.

During the period of 1978 to 1982 in Teknaf laboratory, only 12 strains of <u>Vibrio</u> <u>cholerae</u> were tested for antibiotic sensitivity. All the strains we sensitive to Tetracycline, and all were resistant to Ampicillin. After 1982, no Wibrio strain was tested.

The appearance of Multiple Antibiotic Resistant <u>Vibrio Cholerae</u> (MARVc) in Bangladesh (MU Khan, et , 1986; MI Huq, et al; RI Glass, et al, 1980) and increasing numbers of isolations of <u>Vibrio</u> in Teknaf emphasize the need for further studies in Teknaf, particularly monitoring for MARVc.

Besides Shigella and Vibrios, ICDDR, B studies indicated that Enterotoxigenic Escherichia coli (ETEC) and rotavirus are important aetiologic agents of diarrhoeal disease in rural Bangladesh (RW Ryder, et al, 1976; RE Black, et al, 1980). From

the samples collected during the Water and Sanitation Intervention Study in Teknaf, 8.5% of MacConkey's yielded a positive diagnosis of <u>E.coli</u> containing enterotoxins and 3% of the PBS samples were positive for rotaviruses (MM Rahaman, et al, report of the WSI study in Teknaf, ICDDR, B June 1985). So far, no effort has been made to isolate <u>Campylobacter</u> as an actiologic agent for diarrhocal disease in Teknaf, although ICDDR, B studies suggested that <u>Campylobacter</u> infection is common in Bangladeshi, thildren (MJ Blaser, et al. 1980).

Considering the socio-cultural, topographical, climatic and demographic characteristics of Taknaf, the determination of <u>R</u>. coli, Rotaviruses and <u>Campylobacter</u> as actiologic agents of diarrhocal disease, can certainly widen the understanding of the epidemiology of diarrhocal diseases in similar rural settings.

3. Bationale

Similar surveillance systems are continuining in ICDDR, B Dhaka and Matlab Hospitals. There is no question about the importance of surveillance systems in order to monitor and better characterize the enteric pathogens in both rural and urban settings, and to monitor the changes in morbidity pattern to forecast epidemic outbreaks.

Over 80% of the patients attending the Treatment Centre at ICDDR, B Teknaf are residents of the Teknaf Demographic

Surveillance area with DSS identification numbers, and they can be traced to the household levels. A Shigella epidemiological study is anticipated in Teknaf. But before that we would like a continued utilization of the facilities of ICDDR, B in Teknaf with this surveillance proposal to collect base line information by monitoring the changing pattern and antibiotic sensitivity of the setiologic agents of diarrhoeal diseases.

B. Specific Aims

- Ol. To establish ongoing surveillance of all patients attending the ICDDR, B Treatment Centres in Toknaf, irrespective of residence.
- 02. To determine the actiologic agents of diarrhocal diseases for patients attending ICDDR, B Treatment Centres in Teknaf according to age/sex/clinical picture/seasons.
- 03. To collect information pertinent to epidemiology of diarrhoeal diseases, eg. food history before the onset of diarrhoeal diseases, water uses, uses of latrine, nutritional status, practices of hand washing before taking food and after defaccation, associated illness, uses of ORS/antibiotics, etc.
- 04. To generate new ideas for further research appropriate to controlling diarrhoest diseases, particularly shigellosis.

C. Methods and Procedures

All patients with diarrhoeal disease attending the ICDDR, B's Treatment Centres in Teknaf will be included in this surveillance About 5,000 patients attended the Treatment Centres annually, but recently an increasing attendance has been It has been a regular practice for the last 12 that whenever a patient attends our Treatment Centre, is interviewed and examined by a clinical staff and asked to provide a fresh sample of stool for examination. The patients from required to bring their also DSS for identification. The community has accepted this procedure, and the same procedure will be followed in this surveillance no written consent will be required. Verbal will be obtained from the patients/attending guardians. After completion of history taking and clinical examination, using the set questionnaire, the patient will be asked to provide a sample fresh stool in a clean container (provided by the treatment centre). After collection and proper labelling, the sample will sent to the laboratory for microscopic examination (both saline and iodine preparation) and microbiological culturing for enteric pathogens. If fresh stool sample cannot be collected, R/S sample will be collected for culture. The R/S sample will be streaked in the Treatment Centre on TEA/SS/McC/TTGA plates and the plates, after proper labelling with identification numbers, will be sent to laboratory for incubation. In those cases, stool microscopy will be done later on during followup visits.

laboratory, culture specimens will be processed for Shigella and Salmonells using pathogenic Vibrios, From each culture. 10 lactose laboratory methods. colonies with typical B. coli morphology will be picked from MacComkey's agar plates and preserved on nutrient agar slants. Those will be sent to Dhaka Laboratory periodically for LT & A 10% systematic samples of stool/RS from (when the case number ends with zero) will be inoculated on to a Those plates medium for isolation of Campylobacter. will be incubated in candle jars at 'o 40 C for identification of organisms as Campylobacter jejuni will be done according to standard criteria (MJ Blaser, 1980). A second sample of stool/RS will be collected from each patient under 5 years of age, and will be refrigerated in PBS tubes. Those will be sent to Dhaka Laboratory in ice flasks for further testing for rotaviruses.

Sensitivity to antibiotics (Ampicillin, Tetracycline, Gentamicin, Nalidixic acid, Pivmecillinum and TMP-SXT) will be performed by standard disc diffusion method (AW Bauer et al, 1966) on bacterial isolates; 20% of S.dysenteriae I, 10% of S. flexneri, 10% of other Shigella, 10% of Vibrios and 10% of Campylobacter jejuni will be tested. In the laboratory a list of all positive isolates will be prepared according to the date of testing. From this list, systematic samples as required will be selected for antibiotic sensitivity testing.

For all patients, physical examinations including vital signs, admission weight, state of hydration and signs of nutritional deficiencies, will be done in the treatment centre by the attending Physician/clinical staff. When available, appropriate follow-up entries will be made in the forms. The results of the bacteriological tests will be incorporated in the questionnaire forms. The data collected will be preserved properly. The questionnaire forms will be precoded and completed forms will be sent periodically to Dhaka for computerization. Monthly data analysis will be performed in Teknaf by hand tabulation by tallying the patient data at the end of each month by age/sex/residence/clinical presntation/enteric pathogens.

The hand tabulation result at the end of each month will be distributed to ICDDR, B Treatment Centre staff in Dhaka, Matlab, Chandpur etc. and to Epidemiology Department of ICDDR, B. Quarterly or yearly reports to summarise the finding of the Surveillance Programme will be prepared for distribution to people involved in patient care and data collection. Whenever an epidemic is identified by the Surveillance Programme, Epidemic Control Preparedness Programme of the ICDDR, B will be informed. In collaboration ECPP and local government health authorities, definitive epidemic intervention measures will be undertaken. This type of collaborative programmes will eventually strengthen the resources and responses of Teknaf Treatment Centre to face epidemic outbreaks in Teknaf area in the future.

D. Significance

This surveillance activity will generate a wide range of data on patients attending ICDDR, B Treatment Centres in Teknaf. This surveillance program will monitor the changing pattern of isolation of aeticlogic agents causing diarrhoesl diseases in Teknaf and their susceptibility to antibacterial drugs.

After establishment of this surveillance activity, whenever appropriate, this can be linked to other epidemiological studies in Teknaf or this can serve as a basic data collection unit.

E. Facilities Required

No additional space for office/clinic/laboratory is required. additional logistic support is required. The modified bettery/electric-run incubator supplied by the Dhaka Microbiology Laboratory is renovated for to Campylobactor culture. Laboratory personnel will need inhouse training for isolation of Campylobacter and for the preparation of Campy-BAP medium. determination for E. coli and assays for rotavirus will be Dhaka laboratory. Help from Animal Resources in Blisa will be required. Culture media, drugs, reagents for stationery and computer tapes will be needed.

F. Collaborative Arrangement

None other than inhouse arrangement, will be required.

SECTION LIL

A. DETAILED BUDGET (ICDDH,B Surveillance Programme, Teknaf Treatment Centres)

1. Local Salary, A/C No. 3100

Joh Tille	Level			Amount in US\$
Sr. Lob. Tech	GS - 4	9 ,	228	2,052
Kab. Tech	GS-3	12	302	3,624
Sr. Lab. Attet.	GS2	12	268	3,216
Cleaver	GS-1	12	227	2,724
		s	ub Total	11,616

2. Local Consultant A/C No. 3300

R.O./Sr. Microbiologist;

Dhaka - Teknaf - Bhaka Trip:

Perdiem Twavel Cost	·	· ·	168 172
		Sub Total	340

3. Local Travel A/C No. 3500

Asstt. Scientist, Medical Officer, Lab. Tech;

Teknaf - Dhaka - Teknaf Trip;

Perdiem				-		٠.		168
Air Ticket								200
Ground Expenses		1			,	:		68
Other expense		٠,	•					30
>	•	4						
	•				Siib	Total	'/	1 1213

K/C	No. 3700	÷				
		3702				850
		3704	į			500
		3705	•			1,000
	•	3706		•		150
	1	3707		,		600
		3708				150
•		3709				150
	•	3710	-	•		100
		3712				3,000
		3713				1,000
			;	Sub	Total	7,500
			; (1)			
	r Cost No. 4000					:
		3800				1,500
•	1	4300	•	1		500
•	,		á Q	!		
	ķ			Sub	Total	2,000
• ••	.		• •	٠.		**
	r Deptl. : No. 4800	Services	•	•	·	
11,01	10. 4000		•		*	
		4801				750
		4808				750 750
		4814				100
	w					
			•	Sub	Total	1,600

Total direct operating cost for 1987 US\$ 23,822

SECTION 333

B. BUDGET SUMMARY (ICODR, B Surveillance Programme, Teknaf Treatment Centres)

BUDGET SUMMARY

Expense category

A./C No.	Description	1987 (IN US\$)	
3100	Local salaries	11,616	
3300	Consultant	340	
3500	Travel Local	766	
3700	Supplies & Materials	7,500	
3800	Other costs	2,000	
4800	Inter. Departmental services	1,600	
<u> </u>			· —
Total dir	ect operating costs	23,822	

LITERATURE CITED

- LC Chen, et al.

 Control of Diarrhoeal Diseases Morbidity and Mortality:
 Some Strategic Issues. Proceedings of NAS Workshop on
 effective Intervention to reduce infection in malnourished
 populations. Port-au-Prince, Haiti, June 12-16, 1977.
- WJ Van Zijil, et al.
 Studies on diarrhoeal diseases in seven countries by
 the WHO Diarrhoeal Diseases Advisory Team.
 Bull, WHO, 35: 249-261.
- WH Baker, et al.

 Perspective on acute enteric diseases epidemiology and
 Control. Bull Pan An Health DRS. 9:148-156, 1975.
- JA Walsh, et al.

 Selective primary health care: An interim strategy for disease control in developing countries. N. Eng J Med. 301: 967-974, 1979.
- RE Black, et al.

 A two-years study of bacterial, viral and parasitic agents associated with diarrhoea in rural Bangladesh.

 J Inf Dia. 142(5): 660-666, 1980.
- LC Chen, et al.

 Bpidemiology of death among children in a rural area in Bangladesh. <u>Int J Epi</u>. 9(1): 25-33, 1980.
- ICDDR, B Annual Report, 1986, pp 25
- M Rahman, et al.

 DSS-Teknaf: Vital Events and Migration, 1983. ICDDR, B
 Scientific Report No. 66, August, 1986, pp 4.
- M Rahman, et al.
 The People of Teknaf: Births, Deaths and Migrations
 (1976-1977). ICDDR, B Working Paper No. 13, May, 1979
 pp 24.
- MM Rahaman, et al.

 An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the Bay of Bengal.

 J Inf Dia. 1975; 132: 15-19.
- ICDDR, B Annual Report, 1986, pp 37.

- MR Munshi, et al.
 Plasmid Mediated Resistance To Nalidixic Acid in
 Shigella Dysenterise type 1. The Lancet, August 22,
 187
- MU Khan, et al.

 Epidemiological differences between cholera due to multiple antibiotic resistant and multiple antibiotic sensitive <u>Vibrio cholerae</u> infection. Trans. Roy. Soc. Trop. Med. Hyg. (1986) 80, 60-83.
- MI Huq, et al.

 Studies on Multiply antibiotic resistant <u>Vibrio</u>

 <u>cholerae</u> Ol(MARVc) Biotype Eltor isolated from patients
 with enteritis. Asian Med. J. 27(8): 519-528.
- RI Glass, et al.

 Rmergence of multiply antibiotic resistant Yibrig

 Cholers in Bangladesh. J Inf Dis. 142(6): 939-942,
 1980.
- RW Ryder, et al.

 Entertoxigenic <u>Escherechia</u> coli and rotavirus like agent in rural Bangladesh. <u>Lancet</u> 1: 658-663, 1976.
- MM Rahaman, et al.

 Final Report of The Water and Sanitation Intervention
 Study: Teknaf, Bangladesh, 1980-1983. ICDDR, B June
 1985. pp 70.
- MJ Blaser, et al.

 Isolation of Campylobacter fetue Subar. Jejuni from Bangladeshi children. J Clin Microbia. 12(6): 744-747, 1980.

VERBAL CONSENT STATEMENT (ICDDR, B Surveillance Programme, Teknaf Treatment Centres)

As you know, Teknaf is a hyper endemic area for diarrhoeal diseases, and ICDDR, B is providing you with free investigations and treatment for your diarrhoeal diseases through the treatment centres in Teknaf for last 12 years. It has been a regular practice in ICDDR, B treatment centres that when a patient attends the treatment centre, he is interviewed and examined by a clinical staff and he is also asked to provide a fresh stool sample/rectal awab sample for necessary investigation. Also the patients from the DSS area are required to bring their DSS card, for identification.

is continuing a surveillance programme determination of the changing trend of actiologic agents their antibacterial susceptibility in Teknaf area. Ιf participate in this surveillance programme, you will be provided with usual treatment for your diarrhoeal diseases; we will examine the patient as usually and will need a fresh stool sample/rectal swab sample as we have been doing last 12 years. All the answers you give and all the investigation report will be treated as confidential. If you have any additional question about this surveillance programme, we will try to answer them. We request your participation in this programme by giving your verbal consent. You may, at any time, refuse to participate at your free will; even in that case, you will get usual services from ICDDR, B Teknef.

रपीयिक गया है नज

छन जामगु नर्धरवह ग गुदव्यता । चाम, मि, छि, छि, चाज, वि, दहेर नाम नावा

जाननि निकारि छात्यम्, त्येनमाइत छेम तास्य त्यार गत्न श्रद्भानं त्वनी वन र जानुसाछिक छेम ताम्य गद्यम् । द्वन्ते , त्येन्सेक माना गठ ६६ वश्यतं यावतं वर्षे द्वारगत विकिश्मा छ पायतीय भत्नेकानि विमाधिता नेदतं जानाव्य । वर्षे विकिश्मा द्वारक श्रद्धा श्रद्धाने द्वारगीतं नाम द्वाराम् व्यक्तम मुख्यानमी मात्रा निष्ठ प्रशानि मश्युष्ट कता यम् वप्तर द्वारगीतं मन वा मनमात द्वारम् दम्या खींवानु नदीका कता यम् । कार्षभाती द्वारगी वा भविष्ठित कमा कार्ष निरम् जात्मम ।

वर्षभारत अये शिष्ठकाम जिन्नामग्र द्वाण लुकिनायी विजित्न सीमान ७ जारत विद्वास नामकी अस नाम मेंद्र दल्ल अनि नर्रदक्ष जानाह्य । जानि असे नर्मदक्षण जर्म निर्ण जानाह्य । जानि असे नर्मदक्षण जर्म निर्ण जानाह्य । जानि असे नर्मदक्षण जर्म निर्ण जानाह्य । जानि असे नर्म जा मनदात द्वार करें निष्ठ वृद्ध कर्म अर्थ अर्थ निर्ण नाम्याम नर्मा कर्म निर्ण नाम्याम नर्म कर्म कर्म वर्ष नर्मा स्था मनदात द्वार अर्थ क्षेत्र क्षे

ABSTRACT SUMMARY FOR THE ETHICAL REVIEW COMMITTEE

- 1. All patients attending Diarrhoea Treatment Centres of ICDDR,B in Teknaf Station will be studied. The study will not interfere with the routine medical care. Treatment will be provided as usual, with emergency cases treated on a priority basis. Special questionnaire will be administered by the clinical staff and on duty physician will perform a complete physical examination. Weight will be recorded on admission and on discharge. Stool samples will be examined in the laboratory.
- 2. No risks involved.
- 3. No risk is involved for the patient, so the question does not arise.
- 4. All clinical records will be handled only by the Investigators. Code numbers will be used instead of patient's name.
- 5. Because there will be no risk involved in the patient, only verbal consent will be obtained.
- 6. Approximately 10 minutes will be required to interview the patient/guardian. This will be done in the Treatment Centre after the Clinician has seen the patient and decision of any immediate care has already been made.
- 7. No additional benefit will be gained by the patient. But the data collected will be useful in assessing the quality of medical care provided and making recommendations for its improvement. This will benefit all patients in future. The data collected will allow us to know any change in diarrhoeal disease pattern which is important for taking appropriate measures for treatment and prevention. It also may generate new ideas for future research.
- 8. Stool will be obtained for culture and microscopic examination.

ICDDR,B Surveillance Programme Teknef Treatment Centres

Dia/Dys Reporting Porm

Vall.	Para
Patient's Name:	Father' Name:
Date of previous visit:	·
Study // Card //	
Case #: //_/ Date of STR # // // // // // // // Date of STR # // // // // // // // // // // // // /	of Reporting: /_/_/_/_/
14-23	Sex: /_/ Male = 1, Female = 2
Age (Yr/Mon/Days): /_/_/_/_/_/ 25-30	, •
	// l=<1 day, 2=1-3 days, 3=4-6 days
4=7-9 days, 5=10-12 days, 6=13-15 day	
UL UL	ne, 1=ORS packet, 2=IV Fluid, 3=Combination
OZ-Motor OZ-	/_/ 00=None, 01=Tetra., 02=Furaz.,
	d., 07=Cotrimox., 08=Cepha., 09=Rifamp.,
10=Comb., 11=Antipyratic, 12=Antispasm	o, 13=Cthera (Specify)14=Unknown.
No. of persons eating from same cookin	00 00
No. of household members having dia/dy	a in last 1 month: //
No. of household members having dia/dy	38
Source of water used for drinking:	// l=TW, 2=RW, 3=Ponda, 4=Ditch, 39 5=Spring/fountain
Source of water used for washing/bathi	40
Place of defaecation: /_/ 1=Sanit. 41 4=No fixe	ed place.
Practice of Hand-washing before eating	42 3=Ash & water. 4=Soap & water
Practice of Hand-washing after defaeca	43
Out-side food taken during 3 days before	re onset of dia: // O=No, l=Yes.
Character of starle ()	1=3-5 Times, 2=6-10 Times, 3=11-15 Times, 4=16-20 Times, 5=>21 Times.
Character of stool: // l=Watery, 2:	-Loose, 3=Mucoid, 4=Bloody, 5=3+4.

```
Abdominal pain: /_/ O=No, l=Mild, 2=Mod, 3=Severe.
Prolapse rectus: /_/ O=Absent, l=Present.
Vomiting in last 24 hours: /__/ 0=None, 1=1-3 Times, 2=4-8 Times, 49 3=9-15 Times, 4=16-25 Times, 5=>26 Times.
Fever: /__/ 0=None, 1=Mild, 2=Mod, 3=High
Lest urine passed - hours before reporting: /__/ 0=Upto 6 hrs., 1=7-24 hrs.

51 2=>24 hrs.
History of sickness during last 46 days: /__/ O=None, l=Dia., 2=Dys., 3=Fever, 62 4=ALRI, 5=Measles,
6=Others (Specify)
                                               7=Comb. (Specify)____
PETRICAL PROFIMATIONS
General condition: / l=Normal, 2=Restless, 3=Lethergic/Drousy, 4=Comma.
Clinical assessment of dehydration: /__/ G=None, l=Mild, 2=Nod, 3=Severe.
Oedema feet: / O=None, l=Present.
Anamia: /__/ O=None, 1=Mild, 2=Moderate, 3=Severe.
              /__/ 0=Upto 98.4 F, 1=Upto 100 F, 2=Upto 102 F, 3=>102 F.
Radial pulse: / | l=Normal rate & volume, 2=Rapid & week, 3=Not palpable.
Respiration: / 1=Normal, 2=Faster than normal, 3=Deep & rapid.
Lings: /__/ l=Clear, 2=Congested.
Abdomen: /__/ l=Normal, Sound present, 2=Distended, Sound present, 61 3=Distended, Sound absent.
Prolapse rectum: / 0=None, 1=On Straining, 2=Reduces without aid, 3=Persistent, Oedematous (Swollen).
Weight: /_/_/Kg.
Mutritional status as per weight for age: /___/ 0=0ver 90% standard,
1=75-89% standard (lst.degree), 2=60-74% standard (2nd degree),
3=Below 60% standard (3rd degree). Oedema/Kwashiorkor is always 3rd degree.
Diagnosis: /__/ 1=Uncomplicated diarrhoea, 2=Uncomplicated dysentery, 67 3=Complicated diarrhoea, 4=Complicated dysentery.
                   3=Complicated diarrhoea, 4=Complicated dysentery.
```

INVESTIGATIONS

Stool exams.: // 0=Not done, l=Done, Date: //_/_/_/
Stool character: / 0=Soft, l=Watery, 2=Loose, 3=Mucoid, 4=Bloody, 5=3+4.
Stool pH: / l=Alkeline, 2=Acidic.
REC: // 0=None, 1=Upto 10, 2=11-19, 3=20-29, 4=30-39, 5=40-49, 6=50-59, 7=60-69, 8=70-99, 9=100 or none ner NEF
78 7=50 or more.
Neutral fat: // O=Absent, l=Present.
Stool parasites: /_/_/ 00=None, 01=E.H.(Veg), 02=E.H. (Cyst.), 03=G.L.(Veg)
04=G.L. (Cyst.), 05=Worms (Specify) 06=Combinations (Specify)
Stool culture: /_/ 0=Not done, l=Done, Date: /_/_/_/_/
Organism isolated: /_/ O0=None, O1=S.dys.l, O2=S.flex., O3=Other shigella 04=Vib. NAG., O5=Vib. choleras, O6=Shigella + Vib. O7=Campylo, O8=Rota, O9=ETEC. 10=Combination (Specify)
Antibiotic sensitivity pattern: ///_ 1=Tetra.,2=Amp., 3=Genta. 90-95 4=NA, 6=Pivmec., 6=Ceph. 7=Furaz., 8=SXT-TMP.
TERATREAT
Mode of treatment: /_/ 1=Out-patient, 2=Hospitalized, 3=Referred to other 102 (Specify)
Fluid used: / / O=None, 1=ORS only, 2=1+IV fluid.
Chemotherapy used: / / CO=None, Ol=Tetra., O2=Amp, O3=Genta, O4=NA, 104 105 O5=Pivmec, O5=Chepha., O7=Furaz., O8=SNT-TMP, O9=Metro., 10=Combination, 11=Othera.
FOLLOW-UPS (For two visits within 15 days of first reporting): /_/
00=No visit, 10=1 visit, 11=2 visits
First subsequent visit: /_ / 0=No, 1=Yes, Date: /_ /_ /_ /_ / / / / /
Status of illness after previous visit: // l=Cured 116 2=Condition improving, 3=Condition unchanged 4=Condition deteorating.

Treatment mode: /_ / 1= 116 (S	Admitted, 2=Out patient, 3=Referred to other pecify)
Fluid therapy change to: /	/ Chemotherapy change to: /_/
Further investigations: /_	17 118 _/ O=Hone, 1=Stool M/N, 2=Stool culture,
RESULT:	3 = Antibiotic sensitivity pattern.
Stock M/E: /_/_/_/	//_ Date: //// 127-132
Stool culture: /_/ Dad	te: //// 135-140
Antibiotic sensitivity/res	istance pattern: /_/_/_/_/_/_/
Second subsequent visit:	// 0=No, 1=Yes, Date: //_/_/_/_/
Status of illness after pro	vious visit: // l=Cured
	156 2=Condition improving, 3=Condition unchanged
	4=Condition deteorating.
Treatment mode: /_/ l=/ 157 (Si	dmitted, 2=Out patient, 3=Referred to other
Chemotherapy change to: /	
Fluid therepy change to: /	
Further investigations: /	/ C=None, l=Stool M/E, ·2=Stool culture, 3=Antibiotic sensitivity pattern.
REGLT:	,
Stool M/E: /_/_/_//	// Date: //////
Stool culture: /_/ Dat 174 175	·
Antibiotic sensitivity/resi	stance pattern: /_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_/_

	· •
Signature:	Date Designation

5